青光眼持续给药的眼外、眼周与眼内途径
本文综述青光眼持续释放给药的多种途径与系统:最早获批的Ocusert™为眼表聚合物储库型插入剂,可在眼表零级释放毛果芸香碱一周,但最终退市;目前尚无非侵入性持续释放系统上市。Durysta™为近期获批的房内注射植入剂,用于持续降低眼压,但长期接受度尚未确立;文章还讨论了神经保护疗法的进展。
要点
- Ocusert™曾获批用于青光眼降眼压,置入眼睑下眼表零级释放毛果芸香碱一周,后停产退市。
- 在研持续释放系统包括泪点塞、环型系统、接触镜、植入剂、微球、纳米球、凝胶及眼外、眼周、眼内储库系统。
- Durysta™为近期获批的房内注射植入剂用于持续降眼压,长期接受度尚待确立。
核心结论
- 目前多数抗青光眼药物需多次给药,开发便捷、安全、有效的持续释放给药系统以满足长期治疗需求仍有未满足的临床需要。
- 给药系统的最终成功取决于其相对滴眼液给药的疗效、安全性、报销选择与患者接受度。
- 鉴于既往持续给药途径失败的经验,开发需谨慎推进。
研究设计与样本
- 本文为综述,讨论青光眼持续治疗各种给药途径与给药系统的优缺点,并举例讨论可能应用于青光眼治疗的给药系统。
主要发现
- Ocusert™是一种聚合物储库型插入给药系统,置于眼睑下眼表,一周内零级释放药物,以两种规格上市,在眼表释放毛果芸香碱。
- 尽管许多临床医生认可Ocusert™,该产品最终停产,迄今尚无类似的非侵入性持续释放给药系统上市用于治疗青光眼。
- 在研给药系统包括泪点塞、环型系统、接触镜、植入剂、微球、纳米球、凝胶及其他储库系统,置于眼外、眼周或眼内区域,包括房内、脉络膜上腔与玻璃体腔。
- 一种房内注射植入剂Durysta™近期获批用于持续降低眼压,但此类装置的长期接受度尚未确立。
- 青光眼神经保护疗法包括细胞、基因、蛋白与药物联合疗法,多经玻璃体腔给药,正快速推进至人体评估。
关键数值与推荐
- Ocusert™以两种规格上市,在眼表零级释放毛果芸香碱持续一周。
临床怎么用
- 为青光眼长期治疗选择持续释放给药途径时,需权衡眼外、眼周与眼内途径的优缺点,并综合疗效、安全性、报销与患者接受度谨慎评估。
局限性
- Ocusert™最终停产,迄今无非侵入性持续释放系统上市,Durysta™的长期接受度尚未确立,提示此类系统仍面临疗效、安全性及患者接受度等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although once daily anti-glaucoma drug therapy is a current clinical reality, most therapies require multiple dosing and there is an unmet need to develop convenient, safe, and effective sustained release drug delivery systems for long-term treatment to improve patient adherence and outcomes. One of the first sustained release drug delivery systems was approved for the reduction of intraocular pressure in glaucoma patients. It is a polymeric reservoir-type insert delivery system, Ocusert™, placed under the eyelid and on the ocular surface for zero-order drug release over one week. The insert, marketed in two strengths, released pilocarpine on the eye surface. While many clinicians appreciated this drug product, it was eventually discontinued. No similar sustained release non-invasive drug delivery system has made it to the market to date for treating glaucoma. Drug delivery systems under development include punctal plugs, ring-type systems, contact lenses, implants, microspheres, nanospheres, gels, and other depot systems placed in the extraocular, periocular, or intraocular regions including intracameral, supraciliary, and intravitreal spaces. This article discusses the advantages and disadvantages of the various routes of administration and delivery systems for sustained glaucoma therapy. It also provides the reader with some examples and discussion of drug delivery systems that could potentially be applied for glaucoma treatment. Interestingly, one intracamerally injected implant, Durysta™, was approved recently for sustained intraocular pressure reduction. However, long-term acceptance of such devices has yet to be established. The ultimate success of the delivery system will depend on efficacy relative to eye drop dosing, safety, reimbursement options, and patient acceptance. Cautious development efforts are warranted considering prior failed approaches for sustained glaucoma drug delivery. Neuroprotective approaches for glaucoma therapy including cell, gene, protein, and drug-combination therapies, mostly administered intravitreally, are also rapidly progressing towards assessment in humans.
引用
- Kompella UB, Hartman RR, Patil MA, et al. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog Retin Eye Res. 2020. PMID: 32891866. doi:10.1016/j.preteyeres.2020.100901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。